alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Research

27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.

Find studies

Showing 576–600 of 1,079 studies published 2017 (page 24 of 44) · 27,380 in the whole library · How the 0–100 score works

Download bibliography of the first 500 of these studies, in this order: BibTeX (.bib) · RIS (.ris)

Browse by subject, author or institution

Each number is how many studies that link shows, with your other filters kept.

Subjects

Authors

Names as each record prints them; the same person can appear under two spellings.

Institutions

From OpenAlex; 12,859 studies have no institution on record and are not counted here.

A note on reading research. One study is rarely the final word.

We try to note the size of a study, whether it was in humans or animals, and how early-stage the finding is. If a summary here doesn't make that clear, treat it with extra caution and check the original source.

Evaluating the Patterns of Aging-Related Tau Astrogliopathy Unravels Novel Insights Into Brain Aging and Neurodegenerative Diseases

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of neuropathology and experimental neurology 2017-04-01

The term "aging-related tau astrogliopathy" (ARTAG) describes pathological accumulation of abnormally phosphorylated tau protein in astrocytes. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Chronic cerebral hypoperfusion: a key mechanism leading to vascular cognitive impairment and dementia. Closing the translational gap between rodent models and human vascular cognitive impairment and dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Clinical science (London, England : 1979) 2017-09-28

Increasing evidence suggests that vascular risk factors contribute to neurodegeneration, cognitive impairment and dementia. 2 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

FGF21 Attenuates High-Fat Diet-Induced Cognitive Impairment via Metabolic Regulation and Anti-inflammation of Obese Mice

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Molecular neurobiology 2017-07-15

Accumulating studies suggest that overnutrition-associated obesity may lead to development of type 2 diabetes mellitus and metabolic syndromes (MetS). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Identifying incipient dementia individuals using machine learning and amyloid imaging

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Neurobiology of aging 2017-07-11

Identifying individuals destined to develop Alzheimer's dementia within time frames acceptable for clinical trials constitutes an important challenge to design studies to test emerging disease-modifying therapies. 5 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Prediction of Incipient Alzheimer's Disease Dementia in Patients with Mild Cognitive Impairment

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Journal of Alzheimer's disease : JAD 2017-01-01

The method presented in this paper can be used to separate stable MCI patients from those who are at early stages of AD dementia with high accuracy. 2 key findings →

Participants: 86 Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

AutoDock and AutoDockTools for Protein-Ligand Docking: Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1(BACE1) as a Case Study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Methods in molecular biology (Clifton, N.J.) 2017-01-01

Computational docking and scoring techniques have revolutionized structural bioinformatics by providing unprecedented insights on key aspects of ligand-receptor interaction. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Anti-inflammatory effects of flavonoids in neurodegenerative disorders

✓ Peer-reviewed alzhub usefulness score 47 out of 100. European journal of medicinal chemistry 2017-09-07

Neuroinflammation is one of the main mechanisms involved in the progression of several neurodegenerative diseases, such as Parkinson, Alzheimer, multiple sclerosis, amyotrophic lateral sclerosis and others. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Microglia and C9orf72 in neuroinflammation and ALS and frontotemporal dementia

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The Journal of clinical investigation 2017-07-24

Amyotrophic lateral sclerosis (ALS) is a degenerative disorder that is characterized by loss of motor neurons and shows clinical, pathological, and genetic overlap with frontotemporal dementia (FTD). 3 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Quasi-experimental evaluation of a multifaceted intervention to improve quality of end-of-life care and quality of dying for patients with advanced dementia in long-term care institutions

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Palliative medicine 2017-07-21

Our multidimensional intervention in long-term care facilities for patients with terminal dementia resulted in improved quality of care and quality of dying when compared to usual care. 4 key findings →

Participants: 193 Evidence: low

Full summary, score breakdown and related studies → Original source

Clinical Development of Aducanumab, an Anti-Aβ Human Monoclonal Antibody Being Investigated for the Treatment of Early Alzheimer's Disease

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2017-01-01

The amyloid hypothesis has been the dominant framework for Alzheimer's disease (AD) research, including the development of anti-AD therapies. 2 key findings →

Participants: 196 Evidence: low

Full summary, score breakdown and related studies → Original source

Preclinical and Clinical Development of ABBV-8E12, a Humanized Anti-Tau Antibody, for Treatment of Alzheimer's Disease and Other Tauopathies

✓ Peer-reviewed alzhub usefulness score 47 out of 100. The journal of prevention of Alzheimer's disease 2017-01-01

Tau neurofibrillary tangles are found in the brains of patients suffering from Alzheimer's disease and other tauopathies. 2 key findings →

Design: clinical trial Participants: 30 Evidence: low

Full summary, score breakdown and related studies → Original source

Effect of long-term exposure to air pollution on anxiety and depression in adults: A cross-sectional study

✓ Peer-reviewed alzhub usefulness score 47 out of 100. International journal of hygiene and environmental health 2017-07-03

Our study shows that increasing long-term exposure to air pollution may increase the odds of depression and the use of antidepressants and benzodiazepines. 3 key findings →

Participants: 958 Evidence: low

Full summary, score breakdown and related studies → Original source

Apolipoprotein E4 inhibits autophagy gene products through direct, specific binding to CLEAR motifs

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2017-09-22

ApoE4-CLEAR interactions may account for suppressed autophagy in APOE ɛ4/ɛ4 carriers and, in this way, contribute to earlier AD onset. 1 key finding →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

Limitations of Sacubitril/Valsartan in the Management of Heart Failure

✓ Peer-reviewed alzhub usefulness score 46 out of 100. American journal of therapeutics 2017-03-01

The PARADIGM-HF (Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure) trial was a double-blind trial that randomized 8442 patients with heart failure (HF) with reduced ejection fraction (HFrEF) to receive twice daily dosing of either 200 mg of LCZ696 or 10 mg of enalapril in addition to standard medical therapy for HF. 1 key finding →

Participants: 8,442 Evidence: high

Full summary, score breakdown and related studies → Original source Full text may need a subscription

Efficacy and Safety of an Herbal Therapy in Patients with Amnestic Mild Cognitive Impairment: A 24-Week Randomized Phase III Trial

✓ Peer-reviewed alzhub usefulness score 46 out of 100. Evidence-based complementary and alternative medicine : eCAM 2017-05-17

Herbal therapy demonstrated a significant improvement in cognition and memory, which were similar to the donepezil in patients with aMCI. 3 key findings →

Participants: 216 Evidence: high

Full summary, score breakdown and related studies → Original source Free full text

The relationship between obesity and cognitive health and decline

✓ Peer-reviewed alzhub usefulness score 46 out of 100. The Proceedings of the Nutrition Society 2017-09-11

The relationship between obesity and cognitive impairment is important given the globally ageing population in whom cognitive decline and neurodegenerative disorders will carry grave individual, societal and financial burdens. 4 key findings →

Evidence: low

Full summary, score breakdown and related studies → Original source Free full text

↑ Change the filters

Where “Free full text” comes from

Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read

How the 0–100 score works — and why some entries are capped

This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.

  • Journal tier up to 10 pts
  • Journal's citation record up to 4 pts
  • Study design up to 12 pts
  • Strength of evidence up to 5 pts
  • Peer-review validation up to 10 pts
  • How recent up to 5 pts
  • Sample size up to 4 pts
  • Effect reported up to 3 pts
  • Studied in people up to 3 pts
  • Randomised / blinded up to 2 pts
  • Times cited up to 7 pts
  • Citations per year up to 5 pts
  • Impact for its field and year up to 6 pts
  • Cited by studies here up to 6 pts
  • Still being cited up to 4 pts
  • Senior author's track record up to 4 pts
  • Institution's track record up to 3 pts
  • Multi-centre collaboration up to 3 pts
  • Indexed in PubMed up to 2 pts
  • Free to read up to 2 pts

Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.

Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.

We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.

The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.

See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.

What this library is — and isn't

This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.

1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.

See the full, machine-readable breakdown of this library's coverage →

Newest studies, as a dated timeline →    Atom feed